Chesley Taft & Associates’s Novo Nordisk NVO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $252K | Buy |
3,650
+90
| +3% | +$6.21K | 0.01% | 317 |
|
|
2025
Q1 | $247K | Sell |
3,560
-34
| -0.9% | -$2.36K | 0.01% | 316 |
|
|
2024
Q4 | $309K | Sell |
3,594
-101
| -3% | -$8.69K | 0.01% | 288 |
|
|
2024
Q3 | $440K | Sell |
3,695
-500
| -12% | -$59.5K | 0.02% | 262 |
|
|
2024
Q2 | $599K | Sell |
4,195
-50
| -1% | -$7.14K | 0.03% | 231 |
|
|
2024
Q1 | $545K | Buy |
4,245
+100
| +2% | +$12.8K | 0.03% | 235 |
|
|
2023
Q4 | $429K | Buy |
4,145
+825
| +25% | +$85.3K | 0.02% | 251 |
|
|
2023
Q3 | $302K | Hold |
3,320
| – | – | 0.02% | 258 |
|
|
2023
Q2 | $269K | Hold |
3,320
| – | – | 0.02% | 272 |
|
|
2023
Q1 | $264K | Buy |
+3,320
| New | +$264K | 0.02% | 270 |
|
|
2022
Q2 | – | Sell |
-3,930
| Closed | -$231K | – | 296 |
|
|
2022
Q1 | $231K | Sell |
3,930
-30
| -0.8% | -$1.76K | 0.01% | 284 |
|
|
2021
Q4 | $222K | Buy |
+3,960
| New | +$222K | 0.01% | 290 |
|